CareDx(CDNA) - 2022 Q4 - Earnings Call Presentation

Financial Performance - Q4 revenue reached $82.4 million, a 4% year-over-year increase[9, 60, 64, 83] - Testing services revenue accounted for $65.4 million[9, 60, 64, 83] - Product revenue was $8.6 million[9, 60, 64, 83] - Digital and Patient Solutions generated $8.4 million in revenue[9, 60, 64, 83] - The company holds $293 million in cash and marketable securities[9, 60, 64, 83] - Net loss was ($18.3 million), with an adjusted EBITDA of ($3.7 million)[9, 60, 64, 83] - GAAP gross margin was 64%, while adjusted gross margin was 67%[9, 60, 64, 83] Testing and Volume - Testing volume reached 47,700 tests, a 2% sequential increase and 14% year-over-year increase[9, 60, 64, 83] - Testing represented 73% of the business[8, 20, 50, 52, 59, 64, 72, 82] Future Outlook - 2023 revenue guidance is projected to be between $328 million and $338 million[33, 73]